Proportion of patients with recurrent peptic ulcer or bleeding (full analysis set)
| Visit | Treatment | Recurrent peptic ulcer | Bleeding | ||||
| Estimate % (n/N) | Difference % | 95% CI | Estimate % (n/N) | Difference % | 95% CI | ||
| Week 12 | Lansoprazole 15 mg | 5.0 (10/199) | 2.0 (4/200) | ||||
| Vonoprazan 10 mg | 2.9 (6/209) | –2.2 | −5.941 to 1.632 | 1.0 (2/210) | –1.0 | −3.391 to1.296 | |
| Vonoprazan 20 mg | 3.0 (6/203) | –2.1 | −5.896 to 1.757 | 1.0 (2/199) | –1.0 | −3.379 to1.389 | |
| Week 24 | Lansoprazole 15 mg | 5.5 (11/199) | 2.0 (4/200) | ||||
| Vonoprazan 10 mg | 3.3 (7/209) | –2.2 | −6.182 to 1.826 | 1.4 (3/210) | –0.6 | −3.090 to 1.94] | |
| Vonoprazan 20 mg | 3.4 (7/203) | –2.1 | −6.127 to 1.968 | 1.0 (2/199) | –1.0 | −3.379 to 1.38] | |
| Week 52 | Lansoprazole 15 mg | 7.0 (14/199) | 2.0 (4/200) | ||||
| Vonoprazan 10 mg | 3.8 (8/209) | –3.2 | −7.611 to 1.196 | 1.4 (3/210) | –0.6 | −3.090 to 1.947 | |
| Vonoprazan 20 mg | 5.4 (11/203) | –1.6 | −6.341 to 3.108 | 1.5 (3/199) | –0.5 | −3.068 to 2.083 | |
| Week 76 | Lansoprazole 15 mg | 7.5 (15/199) | 2.0 (4/200) | ||||
| Vonoprazan 10 mg | 3.8 (8/209) | –3.7 | −8.207 to 0.787 | 1.4 (3/210) | –0.6 | −3.090 to 1.947 | |
| Vonoprazan 20 mg | 5.9 (12/203) | –1.6 | −6.523 to 3.271 | 1.5 (3/199) | −0.5 | −3.068 to 2.083 | |
| Week 104 | Lansoprazole 15 mg | 7.5 (15/199) | 2.0 (4/200) | ||||
| Vonoprazan 10 mg | 3.8 (8/209) | –3.7 | 8.207 to 0.787 | 1.4 (3/210) | –0.6 | −3.090 to 1.947 | |
| Vonoprazan 20 mg | 5.9 (12/203) | –1.6 | 6.523 to 3.271 | 1.5 (3/199) | –0.5 | −3.068 to 2.083 | |